Equities

Shield Therapeutics PLC

STX:LSE

Shield Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.75
  • Today's Change-0.10 / -5.41%
  • Shares traded3.82m
  • 1 Year change-74.07%
  • Beta1.5726
Data delayed at least 20 minutes, as of May 17 2024 16:27 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Shield Therapeutics PLC grew revenues 137.95% from 5.50m to 13.09m while net income improved from a loss of 49.79m to a smaller loss of 33.29m.
Gross margin30.78%
Net profit margin-254.44%
Operating margin-239.44%
Return on assets-88.29%
Return on equity-308.60%
Return on investment-136.30%
More ▼

Cash flow in GBPView more

In 2023, Shield Therapeutics PLC increased its cash reserves by 309.99%, or 10.55m. Cash Flow from Financing totalled 49.66m or 379.49% of revenues. In addition the company used 37.13m for operations while cash used for investing totalled 2.43m.
Cash flow per share-0.0446
Price/Cash flow per share--
Book value per share0.0192
Tangible book value per share-0.0023
More ▼

Balance sheet in GBPView more

Shield Therapeutics PLC has a Debt to Total Capital ratio of 57.39%, a lower figure than the previous year's 110.71%.
Current ratio2.28
Quick ratio2.04
Total debt/total equity1.35
Total debt/total capital0.5739
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.